Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) announced inducement equity awards granted on February 1, 2026 under its 2024 Inducement Plan.

The company awarded time-based restricted stock units totaling 30,600 shares to six new employees, vesting one-third annually over three years, subject to continued service. Awards were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – NTLA

+10.73%

6 alerts

+10.73% News Effect

+5.2% Peak in 6 hr 50 min

+$137M Valuation Impact

$1.42B Market Cap

0.3x Rel. Volume

On the day this news was published, NTLA gained 10.73%, reflecting a significant positive market reaction. Argus tracked a peak move of +5.2% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $137M to the company's valuation, bringing the market cap to $1.42B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Pre-news price change: -10.28% Inducement RSUs granted: 30,600 shares Employees receiving grants: 6 employees +3 more

6 metrics

Pre-news price change -10.28% Change over prior 24 hours before this announcement

Inducement RSUs granted 30,600 shares Time-based RSUs granted to new employees on Feb 1, 2026

Employees receiving grants 6 employees New hires awarded inducement RSUs under 2024 Inducement Plan

Vesting schedule One-third annually over 3 years RSU vesting conditioned on continued service

Nasdaq rule cited Rule 5635(c)(4) Inducement grants made in reliance on this listing rule

Inducement Plan year 2024 Inducement Plan Plan adopted by board in June 2024

Market Reality Check

Price: $11.65 Vol: Volume 5,788,068 vs 20-da...

normal vol

$11.65 Last Close

Volume Volume 5,788,068 vs 20-day average 6,880,655 (relative volume 0.84x) indicates typical trading activity. normal

Technical Shares at $11.09 are trading below the 200-day MA of $11.88 and 60.74% under the 52-week high of $28.25.

Peers on Argus

NTLA was down 10.28% pre-news, while key biotech peers like DNTH, ELVN, RCUS, an...

1 Up

NTLA was down 10.28% pre-news, while key biotech peers like DNTH, ELVN, RCUS, and ZYME showed smaller single-digit declines. This suggests a more company-specific move in magnitude rather than a broad sector rotation.

Historical Context

5 past events · Latest: Jan 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 27	Clinical hold lifted	Positive	+6.3%	FDA removed clinical hold on MAGNITUDE-2 Phase 3 ATTRv-PN trial.
Jan 07	Conference appearance	Neutral	+4.1%	Planned presentation at J.P. Morgan Healthcare Conference with webcast access.
Jan 02	Inducement grants	Neutral	+1.7%	RSU inducement grants to two new employees under 2024 Inducement Plan.
Dec 05	Inducement grants	Neutral	-1.8%	RSU inducement awards to three new employees under Nasdaq Rule 5635(c)(4).
Nov 10	Clinical data update	Positive	+2.2%	Longer-term Phase 1 data for nexiguran ziclumeran in ATTR-CM patients.

Pattern Detected

Recent NTLA news, especially clinical and corporate updates, has generally coincided with positive or modest price gains, contrasting with the sharper pre-news decline here.

Recent Company History

Over the past few months, NTLA has reported multiple clinical and corporate updates. On Jan 27, 2026, the FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial, and the stock rose 6.31%. Conference participation on Jan 7, 2026 and repeated inducement grant announcements in Dec 2025 and Jan 2026 produced smaller, mostly positive moves. Longer-term Phase 1 data for nexiguran ziclumeran on Nov 10, 2025 also saw a gain. Today’s routine inducement grants follow this pattern of frequent employment-related equity awards amid ongoing clinical progress.

Market Pulse Summary

The stock surged +10.7% in the session following this news. A strong positive reaction aligns with N...

Analysis

The stock surged +10.7% in the session following this news. A strong positive reaction aligns with NTLA’s history of constructive responses to clinical and corporate milestones, such as the 6.31% gain after the MAGNITUDE-2 hold was lifted and smaller gains on prior inducement grant updates. However, today’s news describes routine hiring-related RSU awards totaling 30,600 shares, so a very large upside move could reflect positioning, liquidity, or broader sentiment rather than the incremental dilution alone.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement plan, +2 more

6 terms

restricted stock units financial

"The inducement grants consisted of time-based restricted stock units (“RSUs”)..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"The inducement grants consisted of time-based restricted stock units (“RSUs”)..."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"These awards were approved... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"under Intellia’s 2024 Inducement Plan as a material inducement to employment."

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

vest financial

"with one-third of such RSUs vesting annually over three years."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

crispr-based therapies medical

"a leading clinical-stage gene editing company focused on... CRISPR-based therapies"

CRISPR-based therapies are medical treatments that use a precise, programmable tool to find and change specific bits of a patient’s DNA, like using molecular scissors to edit a line in a recipe. They matter to investors because successful edits can potentially cure inherited or hard-to-treat diseases, offering high commercial upside, but they also carry long development timelines, regulatory hurdles, safety uncertainties, and manufacturing and intellectual-property risks that affect valuation.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 30,600 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.

Intellia Contact:

Jason Fredette
Vice President, Investor Relations and Corporate Communications
jason.fredette@intelliatx.com

FAQ

What inducement grants did Intellia (NTLA) announce on February 1, 2026?

Intellia granted time-based RSUs totaling 30,600 shares to six new employees. According to the company, the awards were made under the 2024 Inducement Plan as material inducements to employment and were approved by the compensation committee.

How do the Intellia (NTLA) RSUs vest and what are the service conditions?

The RSUs vest one-third annually over three years, contingent on continued service. According to the company, each award requires the employee to remain an employee or service provider through applicable vesting dates for vesting to occur.

Were Intellia's (NTLA) inducement awards granted under existing stock plans or separately?

The awards were granted outside stockholder-approved equity incentive plans under the 2024 Inducement Plan. According to the company, the plan was adopted by the board in June 2024 to permit such material inducement grants.

Why did Intellia (NTLA) use Nasdaq Listing Rule 5635(c)(4) for these grants?

Intellia relied on Nasdaq Rule 5635(c)(4) because the awards were material inducements for new hires granted outside approved plans. According to the company, the compensation committee approved the awards consistent with that Nasdaq listing rule.

How many employees received inducement RSUs from Intellia (NTLA) and when were they granted?

Six new employees received the inducement RSUs, which were granted on February 1, 2026. According to the company, the aggregate award equals 30,600 restricted stock units subject to time-based vesting and service conditions.